Nanjing King-friend Biochemical Pharmaceutical Co Ltd (603707) - Net Assets
Based on the latest financial reports, Nanjing King-friend Biochemical Pharmaceutical Co Ltd (603707) has net assets worth CN¥6.99 Billion CNY (≈ $1.02 Billion USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥10.69 Billion ≈ $1.56 Billion USD) and total liabilities (CN¥3.71 Billion ≈ $542.17 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore net asset growth rate of Nanjing King-friend Biochemical Pharmace to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥6.99 Billion |
| % of Total Assets | 65.35% |
| Annual Growth Rate | 17.29% |
| 5-Year Change | 27.7% |
| 10-Year Change | 424.82% |
| Growth Volatility | 16.87 |
Nanjing King-friend Biochemical Pharmaceutical Co Ltd - Net Assets Trend (2013–2025)
This chart illustrates how Nanjing King-friend Biochemical Pharmaceutical Co Ltd's net assets have evolved over time, based on quarterly financial data. Check Nanjing King-friend Biochemical Pharmace strategic asset allocation index to assess the company's strategic physical and investment asset allocation.
Annual Net Assets for Nanjing King-friend Biochemical Pharmaceutical Co Ltd (2013–2025)
The table below shows the annual net assets of Nanjing King-friend Biochemical Pharmaceutical Co Ltd from 2013 to 2025. For live market cap and overall valuation, see 603707 market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥6.90 Billion ≈ $1.01 Billion |
+6.34% |
| 2024-12-31 | CN¥6.49 Billion ≈ $949.42 Million |
+11.89% |
| 2023-12-31 | CN¥5.80 Billion ≈ $848.50 Million |
-5.98% |
| 2022-12-31 | CN¥6.17 Billion ≈ $902.45 Million |
+14.15% |
| 2021-12-31 | CN¥5.40 Billion ≈ $790.59 Million |
+44.28% |
| 2020-12-31 | CN¥3.74 Billion ≈ $547.95 Million |
+24.65% |
| 2019-12-31 | CN¥3.00 Billion ≈ $439.59 Million |
+24.08% |
| 2018-12-31 | CN¥2.42 Billion ≈ $354.28 Million |
+17.97% |
| 2017-12-31 | CN¥2.05 Billion ≈ $300.31 Million |
+56.11% |
| 2016-12-31 | CN¥1.31 Billion ≈ $192.37 Million |
+20.31% |
| 2015-12-31 | CN¥1.09 Billion ≈ $159.89 Million |
+5.89% |
| 2014-12-31 | CN¥1.03 Billion ≈ $150.99 Million |
+1.33% |
| 2013-12-31 | CN¥1.02 Billion ≈ $149.02 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Nanjing King-friend Biochemical Pharmaceutical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 1067.3% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥4.04 Billion | 58.58% |
| Other Components | CN¥2.86 Billion | 41.42% |
| Total Equity | CN¥6.90 Billion | 100.00% |
Nanjing King-friend Biochemical Pharmaceutical Co Ltd Competitors by Market Cap
The table below lists competitors of Nanjing King-friend Biochemical Pharmaceutical Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
ATS CORP
TO:ATS
|
$1.93 Billion |
|
Nurix Therapeutics Inc
NASDAQ:NRIX
|
$1.93 Billion |
|
Luenmei Quantum Co Ltd
SHG:600167
|
$1.93 Billion |
|
Douglas Emmett Inc
NYSE:DEI
|
$1.93 Billion |
|
Scandic Hotels Group AB (publ)
ST:SHOT
|
$1.93 Billion |
|
Aluar Aluminio Argentino
BA:ALUA
|
$1.93 Billion |
|
Ningbo Shuanglin Auto Parts
SHE:300100
|
$1.93 Billion |
|
Taihai Manoir Nuclear Equipment Co Ltd
SHE:002366
|
$1.93 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Nanjing King-friend Biochemical Pharmaceutical Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 6,491,670,118 to 6,902,863,166, a change of 411,193,048 (6.3%).
- Net income of 581,536,154 contributed positively to equity growth.
- Dividend payments of 218,417,977 reduced retained earnings.
- Other comprehensive income decreased equity by 84,623,453.
- Other factors increased equity by 132,698,324.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥581.54 Million | +8.42% |
| Dividends Paid | CN¥218.42 Million | -3.16% |
| Other Comprehensive Income | CN¥-84.62 Million | -1.23% |
| Other Changes | CN¥132.70 Million | +1.92% |
| Total Change | CN¥- | 6.33% |
Book Value vs Market Value Analysis
This analysis compares Nanjing King-friend Biochemical Pharmaceutical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.91x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 8.05x to 1.91x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-12-31 | CN¥1.01 | CN¥8.16 | x |
| 2014-12-31 | CN¥1.00 | CN¥8.16 | x |
| 2015-12-31 | CN¥1.05 | CN¥8.16 | x |
| 2016-12-31 | CN¥0.98 | CN¥8.16 | x |
| 2017-12-31 | CN¥1.40 | CN¥8.16 | x |
| 2018-12-31 | CN¥1.99 | CN¥8.16 | x |
| 2019-12-31 | CN¥1.88 | CN¥8.16 | x |
| 2020-12-31 | CN¥2.36 | CN¥8.16 | x |
| 2021-12-31 | CN¥3.40 | CN¥8.16 | x |
| 2022-12-31 | CN¥3.82 | CN¥8.16 | x |
| 2023-12-31 | CN¥3.68 | CN¥8.16 | x |
| 2024-12-31 | CN¥3.93 | CN¥8.16 | x |
| 2025-12-31 | CN¥4.27 | CN¥8.16 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Nanjing King-friend Biochemical Pharmaceutical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 8.42%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 14.57%
- • Asset Turnover: 0.39x
- • Equity Multiplier: 1.50x
- Recent ROE (8.42%) is below the historical average (13.04%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | 6.91% | 14.07% | 0.43x | 1.14x | CN¥-31.42 Million |
| 2014 | 4.89% | 12.13% | 0.27x | 1.49x | CN¥-52.70 Million |
| 2015 | 8.01% | 18.68% | 0.36x | 1.19x | CN¥-21.71 Million |
| 2016 | 19.57% | 44.21% | 0.38x | 1.16x | CN¥125.78 Million |
| 2017 | 15.31% | 28.24% | 0.41x | 1.31x | CN¥109.00 Million |
| 2018 | 17.54% | 24.97% | 0.50x | 1.41x | CN¥182.44 Million |
| 2019 | 20.39% | 24.50% | 0.49x | 1.71x | CN¥308.31 Million |
| 2020 | 21.66% | 27.66% | 0.38x | 2.07x | CN¥433.88 Million |
| 2021 | 19.70% | 28.73% | 0.45x | 1.53x | CN¥521.50 Million |
| 2022 | 17.68% | 29.38% | 0.37x | 1.62x | CN¥473.77 Million |
| 2023 | -3.27% | -4.82% | 0.41x | 1.64x | CN¥-769.64 Million |
| 2024 | 12.73% | 21.06% | 0.41x | 1.46x | CN¥176.98 Million |
| 2025 | 8.42% | 14.57% | 0.39x | 1.50x | CN¥-108.75 Million |
Industry Comparison
This section compares Nanjing King-friend Biochemical Pharmaceutical Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $2,254,965,059
- Average return on equity (ROE) among peers: 10.82%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Nanjing King-friend Biochemical Pharmaceutical Co Ltd (603707) | CN¥6.99 Billion | 6.91% | 0.53x | $1.93 Billion |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $1.06 Billion | 5.59% | 4.55x | $681.48 Million |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $560.87 Million | 4.60% | 0.22x | $397.11 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $10.74 Billion | 10.72% | 0.24x | $5.09 Billion |
| Livzon Pharmaceutical Group Inc (000513) | $4.08 Billion | 12.64% | 0.79x | $2.64 Billion |
| Wedge Industrial Co Ltd (000534) | $1.10 Billion | 8.67% | 0.93x | $2.12 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $247.96 Million | 10.36% | 0.27x | $13.37 Billion |
| Hainan Haiyao Co Ltd (000566) | $1.49 Billion | 5.19% | 0.85x | $1.15 Billion |
| Tus Pharmaceutical Group Co Ltd (000590) | $65.32 Million | 20.59% | 1.16x | $316.08 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $1.57 Billion | 22.73% | 1.61x | $1.00 Billion |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $1.63 Billion | 7.16% | 0.55x | $3.20 Billion |
About Nanjing King-friend Biochemical Pharmaceutical Co Ltd
Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of drugs and APIs in China. It also provides heparin sodium, enoxaparin sodium, dalteparin sodium, nadroparin calcium, atracurium besylate, cisatracurium, calcium folinate, doxorubicin, milrinone, bleomycin, carboplatin, cytarabine, topotecan hydrochloride, phenylephrine hydrochlo… Read more